Production of functional coagulation factor VIII from iPSCs using a lentiviral vector

Area of Science:

• Regenerative Medicine
• Gene Therapy
• Hematology

Background:

• Induced pluripotent stem cells (iPSCs) are a potential autologous cell source for cell replacement therapies.
• Hemophilia is a hereditary bleeding disorder requiring effective treatment strategies.

Purpose of the Study:

• To investigate the potential of iPSCs for cell-based therapy of hemophilia.
• To assess the ability of engineered iPSCs to produce functional coagulation factor VIII (FVIII).

Main Methods:

• Mesenchymal stem cells were isolated from C57BL/6 mice and reprogrammed into iPSCs using Oct3/4, Klf-4, Sox-2, and c-Myc.
• iPSCs were transduced with a simian immunodeficiency virus vector to express FVIII.
• Engineered iPSCs expressing FVIII were transplanted subcutaneously into nude mice.

Main Results:

• The derived iPSCs successfully released functional coagulation factor VIII (FVIII).
• Subcutaneous transplantation of FVIII-expressing iPSCs led to teratoma formation and significantly increased plasma FVIII levels.
• Achieved plasma FVIII concentrations were suitable for human therapy within 2-4 weeks post-transplantation.

Conclusions:

• Engineered iPSCs represent a prospective autologous cell source for FVIII production.
• Cell-based therapy using engineered iPSCs holds promise for treating hemophilia.